On Jan. 6, Barry P. Sleckman’s started his job as director of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.
As of September, more than 270,000 deaths have been confirmed in Latin American countries due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
The unprecedented COVID-19 pandemic makes it possible to compare and contrast the public health and political responses to previous health crises.
This January, the American Cancer Society reported the sharpest drop in U.S. cancer mortality ever recorded. Between 2016 and 2017, the death rate from cancer fell 2.2%, continuing the trajectory of a 29% decline in cancer mortality since 1991.
NCI's cancer screening trials may be falling victim to the COVID-19 pandemic.
I write this letter to you as an advocate for women with malignant uterine soft tissue tumors—and to commend you on the introduction of The Uterine Fibroids Research and Education Act in the United States Congress.
I was disappointed to see that you reported on the results of the IMpassion 131 trial, without context. [The Cancer Letter, Sept. 4, 2020]
On behalf of the ECOG-ACRIN Cancer Research Group
NCI's publicly announced move to create an ad hoc working group that would review the feasibility and viability of the TMIST trial threatens to undercut this trial, said Mitchell Schnall, co-chair of ECOG-ACRIN Cancer Research Group, the group conducting the study.
Earlier this summer, NCI Director Ned Sharpless faced a big challenge: produce a video for kids with cancer at Camp Fantastic.
